1/10 #NephJC #TenPostNephJC 💉Bicarbonate is an ICU drug that almost everyone has an opinion on. The physiology is attractive, but evidence isn’t. 🥼SODa-BIC asks if IV bicarbonate improves outcomes in ICU pts with metabolic acidosis on vasopressors. 📄 pubmed.ncbi.nlm.nih.gov/42283370/
Nephrology Journal Club
@nephjc.bsky.social
A twice monthly nephrology journal club that used to meet on Twitter. Hashtag #NephJC www.nephjc.com
#NephJC Live — you're invited NephJC Live Aug 4 2026 9pm EST Paper: Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock (doi.org/10.1056/nejm...) The SODa-BIC study nephjc-live.lovable.app/room/nephjc-... Sign in with your email (one-tap link + code).
Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock | NEJM
Metabolic acidosis is common in critically ill patients and is associated with organ dysfunction and death. Sodium bicarbonate is used to correct acidemia, but its benefit in patients with metaboli...
doi.org
This week we're talkin' about IV Sodium Bicarbonate in the ICU. 💉Does it improve mortality, MAKE30... or just pH? 🥤The SODa-BIC study #NephSky #MedSky www.nephjc.com/news/soda-bic
Buffering without benefit? The SODa-BIC study — NephJC
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rath...
nephjc.com
🖌️ Echa un vistazo al #resumenvisual del ensayo SODa‑BIC realizado por @danyrcal.bsky.social #NephJC www.nephjc.com/news/2026/8/...
🖌️Check out the #visualabstract for the SODa-BIC trial by @danyrcal.bsky.social #NephJC www.nephjc.com/news/2026/8/...
#NephJC #TenPostNephJC FIND-CKD asks: Can we extend nsMRA cardiorenal benefits to the massive population with CKD without diabetes? Let’s FIND out! 🔍 Read the article 👇: pubmed.ncbi.nlm.nih.gov/42246672/ 1/10🧵
Want more?? #NephSky #NephJC 🩳FIND-CKD shorts from @CristinaDeReins Finerenone in glomerulonephritis & a pooled analysis of safety and efficacy in CKD (INFINITY) www.nephjc.com/news/2026/7/20/finerenone-shorts
Finerenone across the proteinuric CKD spectrum — NephJC
Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis
nephjc.com
👀 Seek and you shall FIND 🔎 #ERA26 #NephSky FIND-CKD asks if finerenone is beneficial in patients with non-diabetic CKD. Blog by @manoleaandreea.bsky.social & @divyaveerssneph.bsky.social www.nephjc.com/news/2026/7/6/find-ckd
Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role — NephJC
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effect...
nephjc.com
¿Está la finerenona lista para ir más allá de la diabetes? El resumen visual @drbarbateba.bsky.social @dramiliflores.bsky.social #NephJC #NephSky www.nephjc.com/news/2026/7/17/find-ckd-el-resumen-visual
FIND CKD: El Resumen Visual — NephJC
¿Está la finerenona lista para ir más allá de la diabetes? El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC...
nephjc.com
🔍FIND-CKD🔎 💊Use of finerenone in non-diabetic CKD #NephJC #NephSky #ERA26 VA by @drbarbateba.bsky.social www.nephjc.com/news/2026/7/17/find-ckd-the-visual-abstract
FIND CKD: The Visual Abstract — NephJC
Is finerenone ready to move beyond diabetes? The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD. The next challenge is no...
nephjc.com
#NephJC Shorts is our new way to share quick takes on notable studies we can’t cover fully 👇👇Check the updated blog page for upcoming Shorts and those already published ✨Suggestions and feedback welcome www.nephjc.com/nephjc-shorts
NephJC Shorts — NephJC
nephjc.com
#NephJC #TenPostNephJC. #NephSky 1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes? pubmed.ncbi.nlm.nih.gov/42240165/
🚆 TRACK trial: If thrombosis is at the core of 🫀disease...then DOACs might be helpful in high-risk CKD pts? Maybeeeee... #Nephsky Blog by @nephroseeker.medsky.social & @drsaivani.bsky.social www.nephjc.com/news/2026/7/6/on-the-right-track-rivaroxaban-to-prevent-cardiovascular-events-in-advanced-ckd
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD. — NephJC
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD. Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown ben...
nephjc.com
El resumen visual by @dramiliflores.bsky.social #NephJC #NephTwitter (Que lastima lo de Mexico ⚽️🥅, la proxima sera) www.nephjc.com/news/2026/7/6/track-el-resumen-visual
Track: El Resumen Visual — NephJC
¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada? El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en ...
nephjc.com
This week we're still catching up with #ERA26 The TRACK study 🛤️🩸 #NephJC #NephSky Check out the VA by @drsaivani.bsky.social Can low dose rivaroxaban improve CV outcomes in advanced CKD? www.nephjc.com/news/2026/7/6/track-the-visual-abstract
Track: The Visual Abstract — NephJC
Can rivaroxaban reduce cardiovascular events in advanced CKD? The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high c...
nephjc.com
Meeting number 2 is in the books. 🧑🏫We reviewed how to blog, create a VA, create a post thread and promote on Insta. So many ways to learn and teach #NephJC #NephSky @dramiliflores.bsky.social @drpallaviprasad.bsky.social @nephroseeker.medsky.social @hswapnil.medsky.social @brianrifkin.bsky.social
🚨Another #NephJC 🩳 #NephSky The evidence keeps increasing for new therapies in IgAN🔍 Telitacicept: an APRIL/BAFF inhibitor for decreasing proteinuria in IgAN Blog by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/short/telitacicept7526
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
nephjc.com
🧂New @freelyfiltered.bsky.social episode on hyponatremia correction #NephJC 🍾How can Brussels champagne help with hypoNa? 🎙️ Special invites: Ewot Hoorn @bettercallseeth.bsky.social 🎙️Filtrate: @kidneyboy.bsky.social @hswapnil.medsky.social @nephcrit.bsky.social www.nephjc.com/freelyfilter...
FF93 Hyponatremia Interventional Trial — NephJC
Time to fix the sodium! The Hyponatremia Intervention Trial
nephjc.com
🩳New short from Dr. Sumaiya Ahmed and @hswapnil.medsky.social #NephSky 🔮Can we use prediction models to determine who might benefit from steroids in IgAN before immunosuppression initiation? www.nephjc.com/news/2026/7/1/can-we-predict-who-benefits-from-steroids-in-igan-the-pred-igan-study
Can we predict who benefits from steroids in IgAN? The PRED-IgAN Study — NephJC
Kidney Int . 2026 Apr;109(4):738-749. doi: 10.1016/j.kint.2025.12.024. Epub 2026 Jan 20. A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment i...
nephjc.com
🦵Had our Kick-off meeting today to welcome a new class of #NephJC interns (year 12 and counting). 👁️Keep an eye out for new blog and VA creators. See if you can Catch'em All🎣 #NephSky #MedSky @hswapnil.medsky.social @kidneyboy.bsky.social @nephroseeker.medsky.social @dramiliflores.bsky.social
1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky
The MAJESTRY trial, OBI vs TAC in membranous nephropathy. 👑 Visual abstract by Dr. Divya Bajpai #NephSky #NephJC www.nephjc.com/news/majestytrial
Majesty: The Visual Abstract — NephJC
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy. 👑 Is deeper B-cell d...
nephjc.com
El resumen visual: MAJESTRY trial 👑 @dramiliflores.bsky.social and Dr. Divya Bajpai www.nephjc.com/news/ensayomajesty #NephSky #NephJC
Majesty: El Resumen Visual — NephJC
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa prima...
nephjc.com
Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
nephjc.com
🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates — NephJC
Is measured GFR more accurate than eGFR for forecasting adverse outcomes?
nephjc.com
#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...
Esta vez, @dramiliflores.bsky.social estaba muy ocupada! VA en espanol #NephJC #NephSky #MedSky www.nephjc.com/news/2026/6/1/p9klc2s43l9rrgqifsxgenky9kj81t
Nefrópatia no diabética: El Resumen Visual — NephJC
¿Hemos subestimado la frecuencia de la nefrópatía no diabética (NND) en pacientes diabeticos? Una cohorte basada en biopsias renales de 49,075 pacientes refuerza cuán heterogénea puede ser la NND y de...
nephjc.com
Do you biopsy pts with diabetes? Are you looking for diabetic nephropathy or something else? Check out the blog by @dramiliflores.bsky.social and Dr. Priya John #NephSky #MedSky 📣Now with a "audio abstract" at the top, preview if you want to read more! www.nephjc.com/news/2026/6/1/kidneybiopsy-dkd
Is all kidney disease in Diabetics "Diabetic Nephropathy"? — NephJC
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
nephjc.com
Visual abstract on uncovering non-diabetic-kidney disease in the diabetic patient by @dramiliflores.bsky.social #NephJ #NephSky #MedSky www.nephjc.com/news/2026/6/1/ndkd-the-visual-abstract
Nondiabetic Kidney Disease: The Visual Abstract — NephJC
Have we been underestimating NDKD in patients with diabetes? A biopsy-based cohort of 49,075 patients reinforces just how heterogeneous kidney disease can be in DN and highlights the clinical features...
nephjc.com